TBK1 and cancer: ALTO itself or a small molecule mimic of its TBK1 activating domain could serve as a noncanonical TBK1 agonist for boosting antiviral immunity in immunocompromised individuals, potentially suppressing MCPyV replication and reducing cancer risk.